Navigation Links
Ranolazine Shortens QT Interval and Improves Cardiac Relaxation in Study of Patients With Genetic Sodium Channel Disorder
Date:3/31/2008

the heart. Late sodium current inhibition has been shown to improve mechanical and electrical dysfunctions of cardiac cells under these circumstances.

About CV Therapeutics

CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical company focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases.

CV Therapeutics' approved product, Ranexa(R) (ranolazine extended-release tablets), is indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs, and should be used in combination with amlodipine, beta-blockers or nitrates.

CV Therapeutics also has other clinical and preclinical drug development candidates and programs, including regadenoson, which is being developed for potential use as a pharmacologic stress agent in myocardial perfusion imaging studies. Regadenoson has not been determined by any regulatory authorities to be safe or effective in humans for any use.

Except for the historical information contained herein, the matters set forth in this press release, including statements as to research and development and commercialization of products, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including operating losses and fluctuations in operating results; capital requirements; regulatory review and approval of our products; special protocol assessment agreement; the conduct and timing of clinical trials; commercialization of products; market acceptance of products; product labeling; concentrated customer base; reliance on strategic partnerships and collaborations; uncertainties in drug development; uncertainties
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Study Confirms That New Protocol Shortens the Time It Takes to Open Blocked Arteries for Heart Attack Patients
2. Experimental Drug Ketasyn(TM) Improves Memory in Age-Associated Memory Impairment Study
3. First Osteoporosis Study in Hip Fracture Patients Finds Once-Yearly Reclast(R) Prevents Additional Fractures and Improves Survival
4. New England Journal of Medicine Study Shows ERBITUX(R) Improves Survival in Advanced Colorectal Cancer
5. TREANDA Significantly Improves Clinical Outcomes in Patients with Chronic Lymphocytic Leukemia Compared to Chlorambucil
6. New Approach to Treating Anthrax Significantly Improves Survival Rates in Pivotal Efficacy Studies
7. Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting
8. Tailored Clopidogrel Dosing Improves PCI Outcomes
9. Personalized Medicine - The Genomic Revolution in Cardiac Care
10. FAU Receives Patent for Invention Which Induces and Restores Cardiac Muscle Function
11. Signalife Completes Testing of Modules for Holter and Intra-Cardiac Monitor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)...  Today the U.S. Food and Drug Administration (FDA) announced ... serogroup B meningococcal disease in individuals ages ... received FDA approval in October, represent a significant step ... "I have heard over and over from parents ...
(Date:1/23/2015)... DES MOINES, Iowa , Jan. 23, 2015  The Partnership to ... Iowa health care leaders and a new study ... prescription medications. The PFCD is a nationwide coalition working to educate ... The research released at the Capitol was focused on how the ...
(Date:1/23/2015)... than a third of reproductive-aged women enrolled in Medicaid, and ... a prescription for an opioid pain medication each year during ... Mortality Weekly Report (MMWR). Opioids are typically ... pain.  They are also found in some prescription cough medications. ...
Breaking Medicine Technology:The National Meningitis Association (NMA) Applauds FDA Approval of Second Vaccine To Protect Against Serogroup B Meningococcal Disease 2New research shows Iowa health exchange would benefit from improvements 2New research shows Iowa health exchange would benefit from improvements 3Opioid painkillers widely prescribed among reproductive age women 2Opioid painkillers widely prescribed among reproductive age women 3
... May 11 /PRNewswire-Asia-FirstCall/ -- China Nepstar Chain,Drugstore Ltd. (NYSE: ... China based on the number of directly operated stores,announced today that ... financial results to Tuesday, May 18, 2010 , before,market open. , ... The ...
... SHANGHAI, China , May 11 /PRNewswire-Asia/ -- ... research and development outsourcing company serving the,pharmaceutical, biotechnology, and medical ... United States , today announced its financial results for,first-quarter 2010. ... Highlights, -- First-Quarter 2010 ...
Cached Medicine Technology:China Nepstar Chain Drugstore Reschedules First Quarter 2010 Results to May 18 2China Nepstar Chain Drugstore Reschedules First Quarter 2010 Results to May 18 3WuXi PharmaTech Announces First-Quarter 2010 Results 2WuXi PharmaTech Announces First-Quarter 2010 Results 3WuXi PharmaTech Announces First-Quarter 2010 Results 4WuXi PharmaTech Announces First-Quarter 2010 Results 5WuXi PharmaTech Announces First-Quarter 2010 Results 6WuXi PharmaTech Announces First-Quarter 2010 Results 7WuXi PharmaTech Announces First-Quarter 2010 Results 8WuXi PharmaTech Announces First-Quarter 2010 Results 9WuXi PharmaTech Announces First-Quarter 2010 Results 10WuXi PharmaTech Announces First-Quarter 2010 Results 11WuXi PharmaTech Announces First-Quarter 2010 Results 12WuXi PharmaTech Announces First-Quarter 2010 Results 13WuXi PharmaTech Announces First-Quarter 2010 Results 14WuXi PharmaTech Announces First-Quarter 2010 Results 15WuXi PharmaTech Announces First-Quarter 2010 Results 16
(Date:1/22/2015)... its top dressmaking technologies, has been a leading dress supplier ... latest designs of wedding dresses and launching a site-wide promotion ... the fresh new products are designed for 2015, and they ... All the clothes from LunaDress follow up with the latest ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Gabe’s Chemo Duck Program ... App, the first app ever created for kids with cancer. The ... phones and devices, is filled with enjoyable games to help children ... treatments. The free app helps to keep kids entertained, educated and ...
(Date:1/22/2015)... 22, 2015 The Incredible Bulk is a ... to increase lean muscle by up to 30lbs in less ... attention of HealthyandFitZone.com’s Stan Stevenson, prompting an investigative review. , ... a step-by-step, scientific diet formula that allows the body to ...
(Date:1/22/2015)... 2015 AngelWeddingDress, the premier women’s dress ... wedding dresses. View website of AngelWeddingDress.com to ... maternity wedding dresses online for a bridal party. AngelWeddingDress ... quality for them. Its maternity wedding dresses are specially ...
(Date:1/22/2015)... A new white paper by The ... in the long-term care environment as well as provides ... The paper, “The Power of Person-Centeredness in Long-Term Care: ... of the patient, resident and family experience in long-term ...
Breaking Medicine News(10 mins):Health News:LunaDress Shows The Latest Styles Of Wedding Dresses In 2015 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3
... ... oral ingestion, and this is known to cause jitters and crashing effects. Now there,s a new ... pepper. Spray Awake is the world,s first personal energy spray to use capsaicin as a way ... ...
... 6 CEL-SCI Corporation (NYSE Amex: CVM ), a ... of infectious diseases and a late-stage oncology company, announced today ... School of Medicine (Johns Hopkins) has given clearance for the ... Johns Hopkins will host the study, which will be led ...
... Calif., Nov. 6 California American Water has designated the ... Drain" week for its Sacramento service area as part of ... toward the common mission of reducing pharmaceutical pollution in our ... household items free of charge at: , , ...
... ... the American Heart Association for the Start! Fit-Friendly Companies Award. , ... Covington, LA (PRWEB) November 6, 2009 ... award winning approach to health and lifestyle management and was recently honored with Platinum-Level ...
... CAMBRIDGE, Mass., Nov. 5 ETEX Corporation, an ... with Alphatec Spine, of Carlsbad, California. Alphatec Spine ... substitute portfolio on a non-exclusive basis in the ... http://www.newscom.com/cgi-bin/prnh/20080424/NETH117LOGO ) , Initial sales and ...
... ELA association and Zinedine Zidane, its emblematic ambassador, are ... regaring the gene therapy in adrenoleukodystrophy conducted in France ... Two children have been treated and their diseases have ... unexpected for a disease destroying the brain in a ...
Cached Medicine News:Health News:New Energy Spray Uses Capsaicin to Deliver Caffeine for Sustained Mental Focus 2Health News:CEL-SCI to Conduct First Clinical Study of Investigational LEAPS-H1N1 Treatment for Hospitalized H1N1 Infected Patients at Johns Hopkins University School of Medicine 2Health News:CEL-SCI to Conduct First Clinical Study of Investigational LEAPS-H1N1 Treatment for Hospitalized H1N1 Infected Patients at Johns Hopkins University School of Medicine 3Health News:California American Water Celebrates 'No Drugs Down the Drain' Week in Sacramento 2Health News:Gilsbar is Sole Louisiana Company to Win National Award from the American Heart Association 2Health News:ETEX Corporation Announces Distribution Agreement with Alphatec Spine 2Health News:ETEX Corporation Announces Distribution Agreement with Alphatec Spine 3Health News:2 children suffering from adrenoleukodystrophy saved thanks to the ELA Association 2Health News:2 children suffering from adrenoleukodystrophy saved thanks to the ELA Association 3Health News:2 children suffering from adrenoleukodystrophy saved thanks to the ELA Association 4
... drape sheets with a low-profile, roomy ... the operative site during arthroscopic surgery. ... ports for drainage. , ,The ... a standard pack, or in custom ...
The Quantum II Dual Wavelength Analyzer measures differential absorbances of liquid samples and converts those readings into analytical values....
... The ABBOTT PRISM is a fully ... enhance the safety of the blood supply. ... blood supply, it is tested for evidence ... disease. This screening process involves numerous assays, ...
... The First Consolidated Workstation to Automate ... Slide Staining,Now you can perform deparaffinization, ... and routine slide washing with a ... using preprogrammed Vysis protocols for fluorescence ...
Medicine Products: